The incidence of congestive heart failure (CHF) has increased greatly over the past two decades. Although significant advances have been made in the treatment of CHF, the mortality and morbidity rates remain high, with one year mortality rates of 40% or higher in patients with advanced CHF.

A number of clinical studies have shown that CHF results in neurohormonal alterations such as increased plasma concentrations of noradrenaline, atrial natriuretic peptide, and brain natriuretic peptide (BNP) or activation of the renin–angiotensin system. Of these, BNP appears to be the most powerful neurohormonal predictor of left ventricular function and prognosis. However, myocardial structure is also altered in CHF. Non-contiguous areas of myocardial cell death and foci of replacement fibrosis are typical morphological changes in advanced CHF. Structural abnormalities in viable myocytes are also observed in non-ischaeic CHF, including hypertrophied myocardial cells, degeneration of subcellular organelles, lack of contractile materials, and increased cytoskeletal elements. These morphological changes may be accompanied by an increase in serum cardiac proteins. Myofibrillar proteins may be released into the circulation through degeneration of myofilaments, and cytosolic proteins may be released through leakage due to increased permeability of the membranes of injured myocytes. We were, thus, interested in a fundamental hypothesis that myocardium specific proteins may serve as useful markers for evaluating the severity of congestive heart failure.

Objective: To test the hypothesis that myocardium specific proteins may be useful markers for evaluating the severity of congestive heart failure.

Methods: Serum concentrations of myosin light chain I (MLC-I), heart fatty acid binding protein (H-FABP), creatine kinase isoenzyme MB (CK-MB), and troponin T (TnT) and plasma concentrations of brain natriuretic peptide (BNP) were determined in 48 patients with acute deterioration of congestive heart failure, both before and after effective treatment.

Results: Before treatment, MLC-I (mean (SEM) 3.2 (2.2) µg/l), H-FABP (9.0 (3.5) µg/l), TnT (30 (21) ng/l), and BNP (761 (303) ng/l) were higher than the normal reference range, and concentrations of CK-MB (5.4 (2.9) µg/l) were near normal. Treatment of congestive heart failure with conventional medication significantly decreased the concentrations of MLC-I (1.2 (0.3) µg/l, p < 0.0001), H-FABP (6.0 (2.0) µg/l, p < 0.0001), CK-MB (2.9 (1.5) µg/l, p < 0.0001), TnT (9 (1) ng/l, p < 0.001), and BNP (156 (118) ng/l, p < 0.0001). The decreases in H-FABP and CK-MB concentrations after treatment correlated with the decrease in BNP concentrations (p < 0.05). The absolute concentrations of MLC-I, H-FABP, CK-MB, and TnT correlated positively with those of BNP (p < 0.01).

Conclusions: These findings suggest that MLC-I, H-FABP, CK-MB, and TnT may be used as reliable markers for the evaluation of the severity of congestive heart failure.
were: 4.0 and interassay coefficients of variation, and normal reference
data are expressed as mean (SEM). A paired Student’s
t test was used to compare and analyse differences in continuous
variables that had a normal distribution between the acute
and stable phases. Because the distributions of MLC-I, H-FABP, CK-MB, TnT, and BNP concentrations were skewed
rightwards, median concentrations were computed for these
parameters and expressed as median value (median absolute
deviation). The significance of any difference in medians was
assessed by the Wilcoxon signed rank test and correlations
between these variables were assessed by the Spearman rank
correlation test. A probability value of $p < 0.05$ was considered significant.

**RESULTS**

On admission, all patients had worsening CHF with increased
cardiothoraic ratios on chest radiographs and decreased left
ventricular systolic function on echocardiograms (table 1). The circulating concentrations of BNP were higher than the
normal reference range in all patients (fig 1). Biochemical
analysis showed that serum concentrations of proteins
derived from myocardial cells (MLC-I, H-FABP, and TnT)
were higher than the normal reference range, and the
centrations of CK-MB were near normal (fig 1).

All patients were successfully treated, resulting in improve-
mement of their symptoms and physiological findings; the
NYHA functional class, cardiothoraic ratio, and findings
obtained from echocardiograms all improved (table 1).

**DISCUSSION**

Structural changes associated with severe CHF are character-
ised by degeneration of subcellular organelles in viable
myocytes and multiple foci of myocardial cell death. Thus, we
hypothesised that circulating concentrations of specific
cardiac proteins may be useful as markers for the evaluation
of the severity of CHF. The present study has shown that
circulating concentrations of the cardiac proteins MLC-I, H-
FABP, CK-MB, and TnT correlated with the concentrations of
BNP in patients with CHF. Since circulating BNP concentra-
tions are increased in patients with CHF in proportion to the
severity of the disease, the results of this study suggest that
these specific cardiac proteins may be useful as powerful
markers for determining the severity of CHF.

In the present study in patients with CHF, the concentra-
tions of MLC-I, H-FABP, CK-MB, and TnT were higher on
admission (acute phase) than under the stable conditions
achieved after appropriate treatment. The results are compa-
tible with previous reports that circulating concentrations of

### Table 1 Characteristics of patients

<table>
<thead>
<tr>
<th>NYHA class (I/II/III/IV)</th>
<th>Acute phase</th>
<th>Stable phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>0/11/26/11</td>
<td>32/15/1/0</td>
<td></td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>22.4 (0.7)</td>
<td>20.8 (0.6)**</td>
</tr>
<tr>
<td>Systolic blood pressure (mm Hg)</td>
<td>140.0 (3.8)</td>
<td>118.5 (3.0)**</td>
</tr>
<tr>
<td>Diastolic blood pressure (mm Hg)</td>
<td>77.1 (2.4)</td>
<td>65.6 (2.2)**</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>94.4 (2.7)</td>
<td>74.6 (1.0)**</td>
</tr>
<tr>
<td>Cardiac output ratio (%)</td>
<td>63.8 (0.9)</td>
<td>56.6 (1.2)**</td>
</tr>
<tr>
<td>Left atrial diameter (mm)</td>
<td>42.0 (1.7)</td>
<td>39.4 (1.9)</td>
</tr>
<tr>
<td>Diastolic left ventricular diameter (mm)</td>
<td>62.2 (1.1)</td>
<td>58.4 (1.3)</td>
</tr>
<tr>
<td>Systolic left ventricular diameter (mm)</td>
<td>53.0 (1.3)</td>
<td>46.1 (1.7)**</td>
</tr>
<tr>
<td>Ejection fraction (%)</td>
<td>29.4 (1.8)</td>
<td>42.7 (2.4)**</td>
</tr>
<tr>
<td>Fractional shortening (%)</td>
<td>14.8 (1.0)</td>
<td>22.4 (1.5)**</td>
</tr>
</tbody>
</table>

* $p<0.05$, **$p<0.001$, ***$p<0.0001$ versus acute phase (paired Student’s $t$ test).

NYHA, New York Heart Association.

### Table 2 Medications

<table>
<thead>
<tr>
<th>Medications</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angiotensin converting enzyme inhibitor</td>
<td>19</td>
</tr>
<tr>
<td>Angiotensin II type 1 receptor blocker</td>
<td>15</td>
</tr>
<tr>
<td>α-Blocker</td>
<td>5</td>
</tr>
<tr>
<td>β-Blocker</td>
<td>8</td>
</tr>
<tr>
<td>Calcium channel blocker</td>
<td>9</td>
</tr>
<tr>
<td>Diuretics</td>
<td>48</td>
</tr>
<tr>
<td>Digitalis</td>
<td>29</td>
</tr>
<tr>
<td>Pimobendan</td>
<td>3</td>
</tr>
</tbody>
</table>

Biochemical measurements

For BNP measurement, 3 ml of blood was transferred to a
plastic tube containing 4.5 mg of Na-EDTA and 1500 U of
aprotinin. For measurement of MLC-I, H-FABP, CK-MB, and
TnT, 5 ml of blood was transferred to plastic tubes. Serum
and plasma samples were prepared within 30 minutes of
blood sampling in a precooled centrifuge and were immedi-
ately frozen and stored at $-70°C$. BNP measurements were
made using chemiluminescence immunoassay (Chemilumi ACS,
Centaur, Bayer Medical Co Ltd, Tokyo, Japan). The analytical range, intra-
and interassay coefficients of variation, and normal reference
range (99th centile of the control population) of the assay
were: 0.002–2500 ng/l, 10.9% and 10.6%, < 18.4 ng/l for BNP;
1.0–250 µg/l, 3.0% and 5.1%, < 2.5 µg/l for MLC-I;
1.1–250 µg/l, 3.0% and 3.5%, < 6.2 µg/l for H-FABP;
0.6–500 µg/l, 2.5% and 2.6%, < 5.0 µg/l for CK-MB; and
10–25 000 ng/l, 2.4% and 11.4%, < 10 ng/l for TnT.

Statistical analysis

Data were expressed as mean (SEM). A paired Student’s $t$ test
was used to compare and analyse differences in continuous
variables that had a normal distribution between the acute
and stable phases.

Table 2 Medications

<table>
<thead>
<tr>
<th>Medications</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angiotensin converting enzyme inhibitor</td>
<td>19</td>
</tr>
<tr>
<td>Angiotensin II type 1 receptor blocker</td>
<td>15</td>
</tr>
<tr>
<td>α-Blocker</td>
<td>5</td>
</tr>
<tr>
<td>β-Blocker</td>
<td>8</td>
</tr>
<tr>
<td>Calcium channel blocker</td>
<td>9</td>
</tr>
<tr>
<td>Diuretics</td>
<td>48</td>
</tr>
<tr>
<td>Digitalis</td>
<td>29</td>
</tr>
<tr>
<td>Pimobendan</td>
<td>3</td>
</tr>
</tbody>
</table>
**Figure 1** Serum concentrations of myosin light chain I (MLC-I), heart fatty acid binding protein (H-FABP), creatine kinase isoenzyme MB (CK-MB), troponin T (TnT), and brain natriuretic peptide (BNP) before (acute) and after effective treatment (stable) in patients with congestive heart failure. Open circles: scattergram showing data in each patient; closed diamonds and vertical bars: median value (median absolute deviation). *p < 0.001, **p < 0.0001 versus acute phase.

**Figure 2** Correlations between the decrease in the concentrations of specific cardiac proteins and BNP after effective treatment of patients with congestive heart failure. The decrease in the concentrations of H-FABP and CK-MB, but not of MLC-I and TnT, correlate with that in BNP.
Troponin I, TnT, and MLC-I are increased in advanced CHF. These proteins are specific to myocardial cells, suggesting that the increase in protein concentrations reflects cellular injury of the myocardium in advanced CHF. The presence of myocardial cytosolic proteins such as H-FABP and CK-MB in serum from patients with severe CHF implies that permeability of the membrane of injured myocytes has been compromised and that the release of the cytosolic proteins into the circulation may be caused by leakage. However, this concept does not explain the appearance of MLC-I or TnT in the circulation, as the majority of these proteins are present in the contractile apparatus and not in cytosol. In severe CHF, myofibrils may degenerate and, subsequently, the myofibrillar components may be released into the circulation. Indeed, degeneration of hypertrophied myocardial cells has been reported in human dilated cardiomyopathy. The mechanisms of ongoing myocardial damage in patients with CHF have not been established, but experimental models provide insight into the cellular and molecular mechanisms that contribute to the progression of CHF. Microcirculatory abnormalities of coronary arteries have been implicated in the aetiologies of human cardiomyopathy. These may be contributing factors to focal myocardial necrosis and replacement fibrosis. Recently, other mechanisms have been identified that also mediate the progressive impairment of cardiac structure and function including neurohormonal factors, oxidative stress, and some cytokines. Each of these factors can promote cardiac cell death by producing either myocyte necrosis or myocyte apoptosis through activation of specific genetic pathways. These structural changes may accelerate left ventricular dysfunction, which increases left ventricular filling pressure resulting in secretion of BNP. Thus, it is hardly surprising that circulating concentrations of these specific cardiac proteins correlate with those of BNP in CHF.

Appropriate treatment greatly decreased the concentrations of MLC-I, H-FABP, CK-MB, and TnT, suggesting that the cardiac markers are quite sensitive to changes in left ventricular haemodynamic dysfunction. Strikingly, the decrease in H-FABP and CK-MB concentrations correlated with the decrease in BNP concentrations. This indicates that concentrations of the marker proteins appear to be related to left ventricular filling pressures and can give clinically important information for the treatment of CHF. Since BNP concentrations may serve as a useful prognostic indicator in patients with CHF, the marker proteins may also provide useful information on the prognosis of CHF. BNP and the marker proteins may have a complementary role in the prognostic assessment because BNP and the marker proteins provide intrinsically different information. However, further studies are necessary to confirm this hypothesis.

The interpretation of the present results is limited by the small number of patients studied. However, the clear correlation between the absolute concentrations of the specific cardiac protein markers and of BNP and between the decrease in the concentrations of the cardiac markers and of BNP shows that cardiac proteins may serve as reliable markers for the evaluation of the severity of CHF or the effect of treatment of CHF. Since BNP concentrations do not appear to indicate the severity of CHF in some cases, measurement of the circulating concentrations of these cardiac proteins in combination with BNP may provide more useful information than measurements of BNP concentrations alone in the management of patients with CHF.

**Authors’ affiliations**

T Goto, H Takase, T Toriyama, T Sugiura, Department of Internal Medicine, Enshu General Hospital, Hamamatsu, Japan

K Sato, Department of Internal Medicine, Johoku Hospital, Nagoya, Japan

R Ueda, Y Dohi, Internal Medicine and Molecular Science, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan

---

**Figure 3** Correlations between the absolute values of specific cardiac proteins and of BNP in patients with congestive heart failure. The circulating concentrations of MLC-I, H-FABP, CK-MB, and TnT correlate with those of BNP.
REFERENCES
13 Del Carlo CH, O’Connor CM. Cardiac troponins in congestive heart failure. Am Heart J 1999;138:646–53
17 Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 1997;80:13L–25L
20 Bing OH. Hypothesis: apoptosis may be a mechanism for the transition to heart failure with chronic pressure overload. J Mol Cell Cardiol 1994;26:943–8

IMAGES IN CARDIOLOGY

ICD lead implantation via persistent left superior vena cava

A 67-year-old man with chronic renal failure, hypertension and ischaemic heart disease was admitted for polymorphic ventricular tachycardia with syncope. Echocardiography revealed left ventricular hypertrophy with moderately impaired function. Amiodarone was administered for these arrhythmias, but recurrent episodes were experienced during haemodialysis. Therefore, an implantable cardioverter-defibrillator (ICD) was implanted at the left anterior chest on the other side of the shunt vein. Although the left cephalic vein was too small for insertion of a ventricular lead, an atrial lead was inserted from there, and the ventricular lead was inserted from the left subclavian vein. During the procedure, a persistent left superior vena cava (PLSVC) was detected incidentally, as both leads ran through an unusual left sided downward course. The Medtronic model 6945 (65 cm) screw-in ventricular lead was successfully affixed to the right ventricular apex by forming the stylet into a U shape in the right atrium. The Intermedics model 4385S (52 cm) atrial lead was fixed at the right atrium (see panels). Atrial and ventricular sensing and stimulation thresholds were acceptable. Ventricular fibrillation induced by a T wave shock was successfully defibrillated twice with 20 joules of energy.

PLSVC is present in approximately 0.5% of the population, and a transvenous pacemaker or ICD implantation is sometimes difficult or even impossible in those cases. If transvenous implantation via PLSVC is intended, it is recommended to use a screw-in type electrode with sufficient length so that a loop in the right atrium can be formed for appropriate fixation to the right ventricle.

M Yasuda
Y Nakazato
H Daida
yn kz@med.juntendo.ac.jp

www.heartjnl.com
Circulating concentrations of cardiac proteins indicate the severity of congestive heart failure

T Goto, H Takase, T Toriyama, T Sugiura, K Sato, R Ueda and Y Dohi

*Heart* 2003 89: 1303-1307
doi: 10.1136/heart.89.11.1303

Updated information and services can be found at:
http://heart.bmj.com/content/89/11/1303

These include:

References
This article cites 21 articles, 8 of which you can access for free at:
http://heart.bmj.com/content/89/11/1303#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Drugs: cardiovascular system (8842)
- Heart failure (565)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/